Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ONTY's Cash to Debt is ranked higher than
100% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ONTY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ONTY' s Cash to Debt Range Over the Past 10 Years
Min: 5.92  Med: 169.17 Max: No Debt
Current: No Debt
Interest Coverage No Debt
ONTY's Interest Coverage is ranked higher than
99% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONTY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ONTY' s Interest Coverage Range Over the Past 10 Years
Min: 1060.29  Med: 10000.00 Max: 9999.99
Current: No Debt
1060.29
9999.99
F-Score: 3
Z-Score: -1.00
M-Score: -1.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -50.61
ONTY's ROE (%) is ranked lower than
64% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ONTY: -50.61 )
Ranked among companies with meaningful ROE (%) only.
ONTY' s ROE (%) Range Over the Past 10 Years
Min: -163.15  Med: -65.96 Max: 45.34
Current: -50.61
-163.15
45.34
ROA (%) -45.20
ONTY's ROA (%) is ranked lower than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ONTY: -45.20 )
Ranked among companies with meaningful ROA (%) only.
ONTY' s ROA (%) Range Over the Past 10 Years
Min: -133.9  Med: -50.43 Max: 24.26
Current: -45.2
-133.9
24.26
ROC (Joel Greenblatt) (%) -2859.47
ONTY's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ONTY: -2859.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ONTY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7802.12  Med: -2233.52 Max: 661.83
Current: -2859.47
-7802.12
661.83
EBITDA Growth (3Y)(%) -16.30
ONTY's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. ONTY: -16.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ONTY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60  Med: -12.25 Max: 29.6
Current: -16.3
-60
29.6
EPS Growth (3Y)(%) -16.80
ONTY's EPS Growth (3Y)(%) is ranked lower than
65% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ONTY: -16.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ONTY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.6  Med: -12.65 Max: 28.7
Current: -16.8
-60.6
28.7
» ONTY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ONTY Guru Trades in Q1 2015

Jim Simons 614,178 sh (New)
First Eagle Investment 1,300,000 sh (New)
Murray Stahl 33,333 sh (+3.09%)
Paul Tudor Jones 22,957 sh (unchged)
Steven Cohen 625,000 sh (-13.32%)
» More
Q2 2015

ONTY Guru Trades in Q2 2015

Paul Tudor Jones 63,257 sh (+175.55%)
Murray Stahl 33,333 sh (unchged)
Steven Cohen Sold Out
First Eagle Investment Sold Out
Jim Simons 474,192 sh (-22.79%)
» More
Q3 2015

ONTY Guru Trades in Q3 2015

Murray Stahl 33,333 sh (unchged)
Jim Simons 339,800 sh (-28.34%)
Paul Tudor Jones 44,060 sh (-30.35%)
» More
Q4 2015

ONTY Guru Trades in Q4 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONTY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.06
ONTY's P/B is ranked higher than
88% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. ONTY: 1.06 )
Ranked among companies with meaningful P/B only.
ONTY' s P/B Range Over the Past 10 Years
Min: 0.75  Med: 4.16 Max: 23.93
Current: 1.06
0.75
23.93
Current Ratio 18.25
ONTY's Current Ratio is ranked higher than
88% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ONTY: 18.25 )
Ranked among companies with meaningful Current Ratio only.
ONTY' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 12.00 Max: 36.71
Current: 18.25
1.67
36.71
Quick Ratio 18.25
ONTY's Quick Ratio is ranked higher than
88% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ONTY: 18.25 )
Ranked among companies with meaningful Quick Ratio only.
ONTY' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 12.00 Max: 36.71
Current: 18.25
0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.85
ONTY's Price/Net Cash is ranked higher than
85% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: 5.67 vs. ONTY: 1.85 )
Ranked among companies with meaningful Price/Net Cash only.
ONTY' s Price/Net Cash Range Over the Past 10 Years
Min: 1.04  Med: 5.44 Max: 38.63
Current: 1.85
1.04
38.63
Price/Net Current Asset Value 1.82
ONTY's Price/Net Current Asset Value is ranked higher than
85% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. ONTY: 1.82 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ONTY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.91  Med: 5.20 Max: 38
Current: 1.82
0.91
38
Price/Tangible Book 1.73
ONTY's Price/Tangible Book is ranked higher than
82% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. ONTY: 1.73 )
Ranked among companies with meaningful Price/Tangible Book only.
ONTY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.84  Med: 4.81 Max: 81
Current: 1.73
0.84
81
Earnings Yield (Greenblatt) (%) -142.62
ONTY's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ONTY: -142.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ONTY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -142.63  Med: 23.45 Max: 674.3
Current: -142.62
-142.63
674.3

More Statistics

Revenue(Mil) $0
EPS $ -0.54
Beta2.05
Short Percentage of Float8.11%
52-Week Range $1.00 - 4.69
Shares Outstanding(Mil)94.93

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -0.33 -0.39 -0.40 -0.39
EPS without NRI($) -0.33 -0.39 -0.40 -0.39

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:3O6.Germany,
Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.
» More Articles for NAS:ONTY

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
Edited Transcript of ONTY earnings conference call or presentation 5-Nov-15 9:30pm GMT Jan 12 2016
Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With... Jan 11 2016
Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With... Jan 11 2016
ONCOTHYREON INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors... Jan 11 2016
Is Oncothyreon (ONTY) Stock a Solid Choice Right Now? Dec 31 2015
8 Analyst Stock Picks With 50% to 100% Implied Upside Dec 27 2015
13D Filing From Biotechnology Value Fund On Oncothyreon Reveals 19.8% Stake Dec 21 2015
Where Investors Are Going - Complementary Research on Crocs, Oncothyreon, Nimble Storage and Rexnord Dec 21 2015
ONCOTHYREON INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Dec 21 2015
4 Stocks to Watch Trading Under $500M Market Cap Dec 11 2015
Investor Alert: These 4 Stocks Could Be Ready To Rally Dec 11 2015
Timing is Crucial, Upside Analysis - Analyst Reports on YRC Worldwide, Crocs, Oncothyreon and Nimble... Dec 10 2015
What’s the Deal With These 4 Plunging Stocks? Dec 09 2015
Oncothyreon to Discuss Clinical Data Call scheduled for 4:30 pm ET today Dec 08 2015
ONCOTHYREON INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 08 2015
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without... Dec 08 2015
ONCOTHYREON INC. Financials Dec 08 2015
Do Hedge Funds Love CNX Coal Resources LP (CNXC)? Dec 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK